uniQure N.V. (QURE)
After hours:
| Previous close | 21.24 |
| Open | 21.08 |
| Bid | 20.00 x 800 |
| Ask | 20.82 x 1000 |
| Day's range | 20.53 - 21.08 |
| 52-week range | 12.52 - 28.25 |
| Volume | |
| Avg. volume | 707,645 |
| Market cap | 966.264M |
| Beta (5Y monthly) | 1.12 |
| PE ratio (TTM) | 2.72 |
| EPS (TTM) | 7.60 |
| Earnings date | 23 Feb 2023 - 27 Feb 2023 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 52.00 |
- Motley Fool
3 Growth Stocks That Could Rocket Higher in 2023
If you're looking for stocks that can make dramatic gains quickly, it's hard to do any better than the biotechnology industry. Hardly a week goes by without at least one biotech stock shooting higher or tumbling lower in response to exciting news about experimental treatments. In 2023, all three of these drugmakers will report study results that are awfully important to their futures.
- GlobeNewswire
uniQure Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
LEXINGTON, Mass. and AMSTERDAM, Dec. 20, 2022 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that the Company granted equity awards to employees as a material inducement to commencing their employment. The equity grants were approved by the Company’s board of directors on December 7, 2022, October 31, 2022, and September 27, 2022 (the “Grant Dates”) each in accordance with
- GlobeNewswire
uniQure announces positive CHMP opinion for etranacogene dezaparvovec – gene therapy for adults with hemophilia B
If approved, etranacogene dezaparvovec would be the first licensed gene therapy in Europe for people living with hemophilia BLEXINGTON, Mass. and AMSTERDAM, Dec. 16, 2022 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, announced that its partner, global biotechnology leader CSL (ASX: CSL), has received a positive opinion recommending conditional marketing authorization (CMA) for etranacogen
